...">
Dive Brief: Johnson & Johnson will pay Fate Therapeutics $100 million to co-develop a group of allogeneic, or "off-the-shelf" cell therapies for cancer. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. Current Cathie Wood Portfolio 2023. HighTower Advisors LLC boosted its holdings in shares of Fate Therapeutics by 5.9% in the 1st quarter. The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. All rights reserved. Glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates. Fate Therapeutics will receive a $50 million upfront payment and a $50 million equity investment. The decline is driven in part by the broader sell-off in high growth stocks. Fate Therapeutics, Inc. has appointed Jim Beitel, M.B.A. as Senior Vice President, Corporate Development. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE.". The company's quarterly revenue was up 159.9% on a year-over-year basis. For example, youll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.